In your opinion, where do incretin mimetics fit into the treatment paradigm for type 2 diabetes?
First-line combination therapy with oral agents
After failing 1 oral agent
After failing 2 oral agents
Incretin mimetics represent a new class of therapies for the treatment of type 2 diabetes. The incretin mimetic exenatide is approved by the FDA for the treatment of patients who have failed 1 or more oral therapies. The incretin mimetic liraglutide is currently in phase 3 clinical trials. As a class, incretin mimetics work in a glucose-dependent manner, so they have a relatively low risk of hypoglycemia, although the risk is greater when they are used in conjunction with sulfonylurea therapy. Unlike most other available therapies for type 2 diabetes, incretin mimetics are associated with weight loss instead of weight gain. These agents are administered via injection and have been associated with nausea and vomiting that is generally mild, dose-dependent, and subsides over time.
To learn more about incretin mimetics, please visit the following pages:
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis Glucagon-like Peptide 1 Receptor Agonists: A Novel Treatment for Type 2 Diabetes